Eli Lilly makes strategic investment

Eli Lilly made a strategic investment in Abridge, an AI healthcare company.

By The Desk – Jordan LeahyOctober 26, 2026

Written with the publisher’s AI assistant from Clinical Terminal data. Snapshot as of October 26, 2026; the “Since” list is checked each time this page loads.

Since October 26, 2026

Nothing new on Eli Lilly and Company since this brief was written.

Here's a quick update on recent developments at one of your accounts. This information may be useful for your upcoming conversations.

What moved

Eli Lilly and Company. Eli Lilly made a strategic investment in Abridge. Abridge is growing fast, and we’re expanding our recruiting team to keep pace., Oct 23, 2026

Who This Touches

Andrew Elkind
Chief Financial Officer · MDCalc
Eli Lilly and Company
Pharma

Leadership Eli Lilly and Company

David A. Ricks
Chair and Chief Executive Officer, Eli Lilly and Company
J. Erik Fyrwald
Chief Executive Officer, International Flavors & Fragrances Inc.
Juan R. Luciano
Chair of the Board and Chief Executive Officer, Archer Daniels Midland Company
Daniel M. Skovronsky
Chief Scientific and Product Officer and President, Lilly Research Laboratories, Eli Lilly and Company
Edgardo Hernandez
Executive Vice President and President, Manufacturing Operations, Eli Lilly and Company
Jacob Van Naarden
Executive Vice President; President, Lilly Oncology and Head of Corporate Business Development, Eli Lilly and Company

Sources

Abridge is growing fast, and we’re expanding our recruiting team to keep pace.